Search
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIcotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigationalArtemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy.
R-30490
go.drugbank.com/drugs/DB09179ExperimentalR-30490 is an opioid related to carfentanil used as an animal tranquilizer. … It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives.
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Synonyms: 4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONEMonobenzone
go.drugbank.com/drugs/DB00600ApprovedWithdrawnMonobenzone occurs as a white, almost tasteless crystalline powder, soluble in alcohol and practically insoluble in water. … It exerts a depigmenting effect on skin of mammals by increasing the excretion of melanin from the melanocytes. It may also cause destruction of melanocytes and permanent depigmentation.
Dihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnDihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity.
Synonyms: N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidineSofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalAs a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective … Sofosbuvir is also available as a fixed dose combination product with [DB11613] as the commercially available product Epclusa.
Laquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.
Nitrous acid
go.drugbank.com/drugs/DB09112ApprovedInvestigationalNitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. … It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
Categories: Compounds used in a research, industrial, or household settingEfgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigational[A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG. … Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction